Nymox says data supports Alzheimer's disease test, get $15m for BHP
This article was originally published in Clinica
Executive Summary
A paper published in the January 2008 issue of Expert Review of Molecular Diagnostics concludes that Nymox Pharmaceutical's AlzheimAlert urine test "adds significant useful information in the diagnosis of Alzheimer's disease particularly for the family physician". The FDA has repeatedly refused to grant US marketing authorisation for the test, which detects strands of neural thread protein in urine (see Clinica No 1168, p 20). Nymox markets the test in Europe and offers it in the US as a CLIA-certified diagnostic service. Separately, the company said it had secured $15m in financial commitments. Nymox said it will use the funds to develop its NX-1207 drug for benign prostate hyperplasia and other new products.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.